We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Hematologic Reference Intervals Defined for Newborns

By LabMedica International staff writers
Posted on 05 Jan 2021
Laboratory tests leverage 60% to 70% of medical decisions and one of the most often ordered and impactful tests is the complete blood count (CBC). More...
These decisions require that clinicians have a standard for interpreting laboratory test results for their patients.

Ethical constraints exist for performing an unnecessary needle stick and collecting non-clinically indicated blood samples from this vulnerable newborn population. Many newborn CBC Reference Intervals (RI) publications have been retrospective and some authors cite this as one of their cardinal limitations.

A team of medical scientists associated with the Banner – University Medical Center Phoenix, (Phoenix, AZ, USA) conducted a prospective study at an academic tertiary care center, and hematology samples were collected from 120 participants deemed to be normal healthy term newborns. Study enrollment occurred between May 24, 2016, and November 1, 2017. A total of 170 blood specimens were sent to the laboratory.

The team used a single Sysmex XN-1000 Automated Hematology Analyzer (Sysmex America, Lincolnshire, IL, USA) to generate a CBC with white blood cell (WBC) differential for each newborn, including the advanced hematology parameters. Distributions were assessed for normality and tested for outliers. Reference intervals were values between the 2.5th percentile and 97.5th percentile.

The scientists reported that the novel reference intervals obtained for this study population are as follows: absolute immature granulocyte count, 80/μL to 1,700/μL; immature granulocyte percentage, 0.6% to 6.1%; reticulocyte hemoglobin equivalent, 31.7 to 38.4 pg; immature reticulocyte fraction, 35.9% to 52.8%; immature platelet count, 4.73 × 103/μL to 19.72 × 103/μL; and immature platelet fraction, 1.7% to 9.8%.

The authors concluded their prospective study has defined hematologic reference intervals for this newborn population, including new advanced clinical parameters from the Sysmex XN-1000 Automated Hematology Analyzer. These reference intervals are proposed as the new standard and can serve as a strong foundation for continued studies to further explore their value in diagnosing and managing morbidities such as sepsis, anemia, and thrombocytopenia. The study was published in the January, 2021 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Banner – University Medical Center Phoenix
Sysmex America



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Rapid Molecular Testing Device
FlashDetect Flash10
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.